This protocol is used in executive wellness clinics and shows consistent symptom reduction in observational case series
It was developed as a more stable and potent analog of GHRP-6, designed to interact with the ghrelin receptor (GHS-R1a).[2] Once it binds to GHS-R1a receptors (found in both the hypothalamus and pituitary gland), hexarelin activates phospholipase C (PLC) and inositol triphosphate (IP3) signaling pathways
No studies have examined whether BPC-157 use increases cancer risk, but the concern is biologically plausible
At Balanced Healthcare, peptides are used under medical supervision, and your provider monitors your protocol throughout
Patel (Eds.), Cancer: Oxidative stress and dietary antioxidants (2nd ed.)
Tirzepatide acts on two hormone receptors (GLP-1 and GIP), while semaglutide and liraglutide act on one (GLP-1)